The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Anbenitamab plus albumin-bound docetaxel (nab-docetaxel) ± carboplatin (Cb) versus trastuzumab and pertuzumab plus docetaxel (THP) ± Cb as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer: A randomized, open-label, multicenter, phase 3 trial.
 
Zhi-Ming Shao
No Relationships to Disclose
 
Peng Ji
No Relationships to Disclose
 
Tong Liu
No Relationships to Disclose
 
Huawei Yang
No Relationships to Disclose
 
Yi Zeng
No Relationships to Disclose
 
Xiaoke Hou
No Relationships to Disclose
 
Chunping Liu
No Relationships to Disclose
 
Xiaoping Li
No Relationships to Disclose
 
Nanlin Li
No Relationships to Disclose
 
Zhong Ouyang
No Relationships to Disclose
 
Xiaobo Wu
No Relationships to Disclose
 
Yanxiang Guo
No Relationships to Disclose
 
Guohui Han
No Relationships to Disclose
 
Shien Cui
No Relationships to Disclose
 
Zhijun Zhu
No Relationships to Disclose
 
Yu Zhang
No Relationships to Disclose
 
Wei Huang
No Relationships to Disclose
 
Silong Xiang
No Relationships to Disclose
 
Kai Zou
No Relationships to Disclose
 
Hang He
No Relationships to Disclose